top of page
![Waypoint Partnering Areas cell therapies for oncology](https://static.wixstatic.com/media/061861_900233eafd5246b88359fb9862c69ad2~mv2.png/v1/fill/w_107,h_107,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Waypoint_Partnering_Areas-01.png)
CELL THERAPIES FOR ONCOLOGY
Best-in-class against known targets & first-in-class for novel targets or new modalities.
![Waypoint Partnering Areas Tregs for autoimmune](https://static.wixstatic.com/media/061861_0933ab27c94d4fb393322684c0b0e8e4~mv2.png/v1/fill/w_107,h_107,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Waypoint_Partnering_Areas-02.png)
TREGS FOR AUTOIMMUNE
Regulatory T cells therapies to treat autoimmune diseases. Optimized for therapeutic efficacy and manufacturing.
![Waypoint Partnering Areas target identification and prioritization](https://static.wixstatic.com/media/061861_625e3ea9beba4636a9d6949d39241afa~mv2.png/v1/fill/w_107,h_107,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Waypoint_Partnering_Areas-03.png)
TARGET ID & PRIORITIZATION
Human genetics-based target ID and prioritization. Allelic series & deep profiling of in vivo phenotypes.
bottom of page